A.C.M. van den Bergh

No picture available
E-mail:
a.c.m.van.den.bergh umcg.nl

Research

  1. 2019
  2. Westgeest, H. M., Kuppen, M. C. P., van den Eertwegh, A. J. M., de Wit, R., Coenen, J. L. L. M., van den Berg, H. P. P., Mehra, N., van Oort, I. M., Fossion, L. M. C. L., Hendriks, M. P., Bloemendal, H. J., van de Luijtgaarden, A. C. M., Huinink, D. T. B., van den Bergh, A. C. M. F., van den Bosch, J., Polee, M. B., Weijl, N., Bergman, A. M., Uyl-de Groot, C. A., & Gerritsen, W. R. (2019). Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands. Clinical genitourinary cancer, 17(5), E946-E956. https://doi.org/10.1016/j.clgc.2019.05.018
  3. Groot, H. J., Lubberts, S., De Wit, R., Witjes, J. A., Kerst, J. M., De Jong, I. J., Groenewegen, G., Van Den Eertwegh, A. J. M., Poortmans, P. M., Klümpen, H. J., Van Den Berg, H. A., Smilde, T. J., Vanneste, B. G. L., Aarts, M. J., Incrocci, L., Van Den Bergh, A. C. M., Jozwiak, K., Van Den Belt-Dusebout, A. W., Horenblas, S., ... Schaapveld, M. (2019). Re: Risk of solid cancer after treatment of testicular germ cell cancer in the platinum era. Journal of Urology, 201(3). https://doi.org/10.1097/01.JU.0000553704.62228.49
  4. 2018
  5. Groot, H. J., Gietema, J. A., Aleman, B. M. P., Incrocci, L., de Wit, R., Witjes, J. A., Groenewegen, G., de Brouwer, P., Meijer, O. W. M., Hulshof, M. C. C. M., van den Berg, H. A., Smilde, T. J., Vanneste, B. G. L., Aarts, M. J., van den Bergh, A. C. M., Kerst, J. M., van den Belt-Dusebout, A. W., Lubberts, S., Jozwiak, K., ... Schaapveld, M. (2018). Risk of diabetes after para-aortic radiation for testicular cancer. British Journal of Cancer, 119(7), 901-907. https://doi.org/10.1038/s41416-018-0248-x
  6. Groot, H. J., Lubberts, S., de Wit, R., Witjes, J. A., Kerst, J. M., de Jong, I. J., Groenewegen, G., van den Eertwegh, A. J. M., Poortmans, P. M., Kluempen, H-J., van den Berg, H. A., Smilde, T. J., Vanneste, B. G. L., Aarts, M. J., Incrocci, L., van den Bergh, A. C. M., Jozwiak, K., van den Belt-Dusebout, A. W., Horenblas, S., ... Schaapveld, M. (2018). Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era. Journal of Clinical Oncology, 36(24), 2504-2513. https://doi.org/10.1200/JCO.2017.77.4174
  7. Van Vreeswijk, N. L., Hammer, C., Van den Bergh, A. C. M., Vanhauten, H. A. M., Bijmolt, S., Langendijk, J. A., & Aluwini, S. (2018). Long term toxicity after radiotherapy for prostate cancer: NTCP models for rectal toxicity.. S332. Abstract from 37th Meeting of the European-Society-for-Radiotherapy-and-Oncology (ESTRO), Barcelona, Spain. https://doi.org/10.1016/S0167-8140(18)30936-8
  8. 2017
  9. 2016
  10. Bolla, M., Maingon, P., Carrie, C., Villa, S., Kitsios, P., Poortmans, P. M. P., Sundar, S., van der Steen-Banasik, E. M., Armstrong, J., Bosset, J-F., Herrera, F. G., Pieters, B., Slot, A., Bahl, A., Ben-Yosef, R., Boehmer, D., Scrase, C., Renard, L., Shash, E., ... Collette, L. (2016). Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991. Journal of Clinical Oncology, 34(15), 1748-1756. https://doi.org/10.1200/JCO.2015.64.8055
  11. 2015
  12. 2014
  13. 2013
  14. 2012
  15. Bolla, M., van Poppel, H., Tombal, B., Vekemans, K., Da Pozzo, L., de Reijke, T. M., Verbaeys, A., Bosset, J-F., van Velthoven, R., Colombel, M., van de Beek, C., Verhagen, P., van den Bergh, A., Sternberg, C., Gasser, T., van Tienhoven, G., Scalliet, P., Haustermans, K., Collette, L., & European Org Res Treatment Canc (2012). Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). LANCET, 380(9858), 2018-2027. https://doi.org/10.1016/S0140-6736(12)61253-7
  16. 2011
  17. 2010
  18. 2009
  19. Matzinger, O., Duclos, F., van den Bergh, A., Carrie, C., Villa, S., Kitsios, P., Poortmans, P., Sundar, S., van der Steen-Banasik, E. M., Gulyban, A., Collette, L., Bolla, M., & EORTC Radiation Oncology Grp (2009). Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991. European Journal of Cancer, 45(16), 2825-2834. https://doi.org/10.1016/j.ejca.2009.07.009
  20. Bolla, M., de Reijke, T. M., Van Tienhoven, G., Van den Bergh, A. C. M., Oddens, J., Poortmans, P. M. P., Gez, E., Kil, P., Akdas, A., Soete, G., Kariakine, O., Van der Steen-Banasik, E. M., Musat, E., Pierart, M., Mauer, M. E., Collette, L., EORTC Radiation Oncology Grp, & Genito-Urinary Tract Canc Grp (2009). Duration of Androgen Suppression in the Treatment of Prostate Cancer. New England Journal of Medicine, 360(24), 2516-2527.
  21. Matzinger, O., Poortmans, P., Giraud, J-Y., Maingon, P., Budiharto, T., van den Bergh, A. C. M., Davis, J. B., Musat, E., Ataman, F., Huyskens, D. P., Gulyban, A., Bolla, M., & EORTC Radiation Oncology Grp (2009). Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: Dummy run and individual case review. Radiotherapy and Oncology, 90(3), 285-290. https://doi.org/10.1016/j.radonc.2008.10.022
  22. 2008
  23. 2007
  24. Roenhorst, A. W. J., van den Bergh, A. C. M., van Putten, J. W. G., & Smit, E. F. (2007). Iris metastasis in small-cell lung carcinoma. Journal of Thoracic Oncology, 2(12), 1128-1129.
  25. Poortmans, P., Bossi, A., Vandeputte, K., Bosset, M., Miralbell, R., Maingon, P., Boehmer, D., Budiharto, T., Symon, Z., van den Bergh, A. C. M., Scrase, C., Van Poppel, H., & Bolla, M. (2007). Guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC Radiation Oncology Group. Radiotherapy and Oncology, 84(2), 121-127. https://doi.org/10.1016/j.radonc.2007.07.017
  26. 2004
  27. Creutzberg, C. L., van Putten, W. L. J., Warlam-Rodenhuis, C. C., Van den Bergh, A. C. M., De Winter, K. A. J., Koper, P. C. M., Lybeert, M. L. M., Slot, A., Lutgens, L. C. H. W., Kroese, M. C. S., Beerman, H., & van Lent, M. (2004). Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: The postoperative radiation therapy in endometrial carcinoma trial: The postoperative radiation therapy in endometrial carcinoma trial. Journal of Clinical Oncology, 22(7), 1234 - 1241. https://doi.org/10.1200/JCO.2004.08.159
  28. 2003
Previous 1 2 Next

ID: 47060